Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$11.99 USD

11.99
4,400,799

+0.03 (0.25%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sweta Jaiswal, FRM headshot

Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain

Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.

Coronavirus Vaccine Efforts Key to Novavax (NVAX) Q2 Earnings

Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.

Sanghamitra Saha headshot

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

What's in Store for Novavax (NVAX) This Earnings Season?

Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.

The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax

The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

Novavax (NVAX) closed the most recent trading day at $140.69, moving +1.78% from the previous trading session.

3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data

Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.

Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress

Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

Novavax (NVAX) closed the most recent trading day at $111.15, moving +1.07% from the previous trading session.

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson

The Zacks Analyst Blog Highlights: Etsy, TMobile US, Anthem, Novavax and Southwest Gas

The Zacks Analyst Blog Highlights: Etsy, TMobile US, Anthem, Novavax and Southwest Gas

Tirthankar Chakraborty headshot

Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight

Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.

Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

Is (NVAX) Outperforming Other Medical Stocks This Year?

Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).

Tirthankar Chakraborty headshot

Coronavirus to Cast a Pall Over Q2 Earnings: 5 Stocks to Stand Out

It will be prudent to invest in companies from the tech, healthcare and utility sectors, which are expected to have suffered less compared to others in Q2.

Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals

Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.

Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Company News for Jul 8, 2020

Companies In The News Are: WMT, NVAX, DOCU, REGN.

Novovax Up on $1.6B Federal Funding for Coronavirus Program

Novovax (NVAX) is evaluating a coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. A pivotal study is due to start in the fourth quarter.

Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine

Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.

Kinjel Shah headshot

FDA Issues Guidance for Coronavirus Vaccine Developers

Around a dozen companies are developing a vaccine for the deadly coronavirus disease.

Sanghamitra Saha headshot

Top Leveraged ETFs of Last Week

Leveraged gold miners and treasury ETFs gained last week despite a market crash.

The Zacks Analyst Blog Highlights: Microvision, Veritone, Remark, Novavax and DCP

The Zacks Analyst Blog Highlights: Microvision, Veritone, Remark, Novavax and DCP

Sweta Killa headshot

Growth Investing Leads in 1H: 5 Top ETFs & Stocks

Growth investing took a lead so far this year courtesy of massive money flowing into the economy.